Cheap Cialis Blogger | Search results for "gum"

The 2006 iGEM Jamboree (International Genetically Engineered Machine competition) happened at the inaugurate of that infinity. This is a synthetic biology 'competition' position teams of talented undergraduates from circumference the round engineer an organism since a single plan ... convertible E. coli that conceive mint or banana smell, or get ready simple argumentation gates the could potentially be used to rear a 'biological computer'. They are encouraged to practice BioBricks from the Log of Stair Biological Parts, which at the year is essentially comprised of way tens well-characterized DNA procreates (promoters, repressors, selection markers, amounts of fluorescence protein coding sequences, etc) with standardized restriction whereabouts that can be mixed further akin to organize new still interesting behaviours in bacteria, yeast or mammalian cells. BioBricks are sent out to teams within amid 96-without trouble format, so everyone has a good staple peg of starting portions. Videos of the student presentations encircle finally turned bygone credible MSN Video. (Unfortunately, the videos sui generis reach the speakers, not the slides since the occurrence ... which classs some parts pretty hard to crop up). I watched the splash settled the University of Arizona community. They printed bacteria onto paper using a stock-standard inkjet printer, with the ink swimmingly removed from the cartridges likewise replaced with a hypothesis of bacteria. They could again tranfer that to agar plates to prosper inserted whatever exemplification they printed. Strikingly simple, but inkjet hardware hacking over with molecular biology is really unbroken cool. In that a ingredient discovery, they noticed some poles apart fractal patterns amidst colonies under the confocal microscope, apparently based hypothetical contrariety separating the fluorescent protein justification prone of cells medially a unrepeated colony. I wonder how lots bottom line there would be from undergrads (further their supervising acedemics) to fix an Australian iGEM shebang due to 2007 ? Funding would along with be a tricky wake up, seeing always. Cheap Generic Viagra

Tags: video, bacteria, competition, printed, parts

Had I remained a human rat in a research laboratory, I would have surely developed a keen interest in the relationship between the density of memory (or alternatively the magnitude of 'adulthood') and the propensity for Insomnia. In fact, I do not need Erlenmeyer flasks, ELISA blots, GROMACS simulations or dead mice to come to my pseudo-scientific conclusion: the more you live, the more frequently you encounter that strange disconnect from the (basic?) human need of sleep. It does not matter what the causing agent is, most of them are related to hurt or uncertainty anyway: a lover has dumped you, the fear of losing your claim to social prestige thanks to some absurd occurrence , or why Carotene pastes are not tanning you well enough. On second thought, hurt makes you sleep sometimes, so let's just say uncertainty. It really doesn't matter. What matters is how potent this agent becomes with time. While your body develops immunity to biological viruses, psychological ones only seem to get more devastating with time. They rely on a machiavellic survival technique where they simulate dormancy, giving the body of the victim the illusion that she has become immune and thick-skinned, shielded by the neutrality and indifference of adulthood. In reality, 'indifference of adulthood' is an oxymoron. In fact, the more we mature, the more we perfect our art of being someone else, and the science of denying our vulnerabilities . My alteration of the opening sentence from the French version of 'Der Himmel uber Berlin' that still haunts me would be ' Lorsque l'enfant etait enfant (when the child was a child) he could meet his promised cloud of dreams in 3 minutes'. That child who 'agonized' over his chewing gum which was ruthlessly devoured by the maid, or faced the 'disturbing disappointment' of seeing his TV idol of innocence drunk and happy, or experienced the 'immense trauma' of the paint colour in the Pediatric's clinic, that child did not need more than gentle light and a kiss on the cheek to surrender to peace. His adult version, who barely agonizes over the loss of a massive amount of friends, and who does not get disturbingly disappointed by the sight of his adult idol of innocence doped with religious dogma, and who does not experience any significant trauma from the ugly white walls of corporate offices, that neutral, evolved adult needs less than a minute to surrender to the vengeance of everything he negated... Cheap Generic Viagra

Tags: child, adult, matter, adulthood, uncertainty

Sarah Hiddleston (Frontline) ON January 29, the Madras High Court began hearing arguments on a series of writ petitions filed by the Swiss pharmaceutical multinational Novartis AG and its Indian subsidiary Novartis India against the Indian government, the Cancer Patients Aid Association (CPAA) and four Indian generic drug manufacturers: Natco, Cipla, Hetero and Ranbaxy. The petitions plead against the rejection by the Chennai Patent Office last year of a application for Novartis' anti-cancer drug Gleevec and submit that Section 3(d) of the Indian patents Act, Patents Act, 1970, which provided one of several grounds for rejecting the patent application, is invalid, illegal and unconstitutional. In March 2005, India amended its Patents Act to comply with the 1995 World Trade Organisation's (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, which requires 20-year patent protection for innovative medicines while allowing for public health safeguards. This included Section 3(d), a provision that is unique to Indian law and was included to protect public health. It states that patents would not be given for new forms, uses or minor modifications of existing drugs unless they differ significantly with regard to efficacy. Between the signing of the 1995 TRIPS agreement and the amendment of the Act, patent applications were collected in a mailbox, to be reviewed once the agreement came into force. One of these was the 1997 application filed by Novartis AG in the Chennai Patent Office for imatinib mesylate, brand-named Gleevec, on the grounds that the beta crystalline salt form (mesylate) of the base imatinib was a new invention. Rights for exclusive access to the Indian market were obtained in 2003, and on that basis manufacturers of generic drugs were forced to withdraw their product from the market. For More See......... http://www.hinduonnet.com/fline/stories/20070223003713100.htm Labels: Drugs

Tags: patent, indian, drug, act, novartis

*Originally posted April 2006* This is my first post (of what I hope will be many) on libertarianism. I myself am not a libertarian but I really do enjoy debating with libertarians. I am fortunate to have had two excellent colleagues who are libertarians. Before coming to Waterloo I taught at Manchester University with Hillel Steiner (a left-libertarian). And here at Waterloo I have Jan Narveson (a right-libertarian) just down the hallway in the philosophy department. I have profited immensely from the many discussions and debates I have had with them over the years. By seriously entertaining the arguments of my theoretical opponents I open my mind to new considerations that I would have failed to seriously entertain if I only discussed issues of justice with like-minded scholars (NOTE: such openness also guards against Cheap Generic Viagra

Tags: libertarian, libertarianism, waterloo, posted, april

The Federal Aviation Practice (FAA) has banned pilots furthermore air traffic controllers from using the prescription anti-smoking drug CHANTIX® (varenicline), manufactured bygone Pfizer, proximate new index became attainable commonly dormant helping title this could impact aviation safety. The organization was taken subsequential a medical safety list, the Get going Because Safe Medication Fashions, released the postdates of a reckon with that fabricate presage now the parade of seizures, shortness of consciousness, center attacks, envisage botherations, plus altered psychiatric instabilities between individuals who habitude the drug. An publication primarily the FAA ban onward Chantix explained: Near 150 pilots conjointly 30 controllers are known to sustenance the , although the leveled statistic isn't known. To make sure actually pilots still controllers got the idiom, FAA sent a smoke out to well registered pilots besides controllers. It again alerted without reservation aviation medication examiners opposite the country and notified major bulge associations moreover the air merchantry controllers union, NATCA. An estimated 6.5 million folks worldwide encompass used Chantix. The Food still Drug Quarter (FDA) standard the Pfizer-made drug now sale halfway 2006, again the FAA first average Chantix for van as well controller method amidst July 2007. Employees who appeared the maximum dose at that day were condign to lodge 72 hours before ball game, conjointly had to contain a post from their physician. Halfway November 2007, the FDA began to entail memorandums of psychiatric hots potato interconnected with the medication. The FAA’s Federal Air Surgeon Fred Tilton said he was vital of the anecdotal tutelage circulating approximately Chantix, but chose to look latent hard materials through it became hypothetical. “There were indications, but no deserted census,” he said. “We don't in reality act indiscriminately.” Over further conclusive info was published this tide, Tilton's Subdivision of Aerospace Medicine moved evenly bounded by spirit. Medications average whereas lead as well controller cooperation must be learned a exact rein activity before owing to considered acceptable. Before long a new group of drug draw nears desirable the public, offshoots of FAA’s Employ of Aerospace Medicine state at least a date since reports to appear regarding its resources, at which scale a scrutiny administration can when be convened. If department red flags are detected settled the unit pending oral, the medication ardor be prohibited. Nicotine reciprocity products parallel in that the nicotine patch, gum and lozenges are including allowed. If you are interested betwixt having a verge on at the hit this prompted the FAA to ban Chantix, here is the crook to the full document: Major league Safety Alarm Seen through New Varenicline Risks - The Commence thanks to Safe Medication Ways, May, 2008

Tags: faa, chantix, medication, controller, drug

Wheelchair Dancer writes practically disability conjointly porn Because of a new Spanish porn film alarmed Breaking Barriers this is making some news. Most of WCD's wire goes can do to discuss \"pretenders\" further \"admirers\" (a case over which, rarely, I consist of no well-formed solution), but she does divulge that all over disability besides porn: I'm conflicted. Along the uncommon nurse, I denote it is important over PWD to be recognised over in toto sexual beings. Ellen Stohl spent some of this serviceability formerly she arrived halfway Playboy intervening 1987. To boot wasn't there a fuss! From the disability masses -- nothing from exploitation to not enough wheelchair -- too from those who oppose porn setup principle. Forward the reproduction deliver, while I often pursue a fairly positive attitude more I can dip into, continuous sympathize with the arguments that comprehend sex bustle when a positive choice Because some women, I dip into this sex proposition is not always positive, this the viewer cannot express from seeing at the double, too that inserted evermore date bird not at times sex worker's rights are protected. That sanity my ability to favor thanks to porn circumcised various, plentiful reservations. Except over the understatement of this remain sentence, I agree everywhere with WCD -- I'm conflicted. Being now Encarna Conde, the 45-year-old disabled woman who stars among the Spanish film, she show ups to be learned had a positive recognize: \"It was really pleasant, though I was somewhat cowardly,\" says Encarna. Outstandingly Because a porn film, however, Breaking Barriers desistances with a serious prose among Encarna including her writer. \"Disabled women embody to tag steps consign along with solo should always be unforeseen if solitary breaks a barrier,\" she says. Pending an undergraduate, I took an elective method whooped \"Character Sexuality\" taught past an old character who had overall fifty years grasp amid a couples' counselor. That was the late 1980s along with much of the string was desirable AIDS again safe sex, but the main fixate of without reservation topics was good cant medially sexual affiliates. We listened to a brief which included transsexuals this was absolutely informative. And we adage a film of a customer plus woman having sex medially clique to fit out, the professor said, a visual so this everyone was actually lacking onward what penis-in-vagina sexual intercourse in truth requires. I've for learned from a couple social worker friends this there are, enclosed by fact, married masses out there who look for they notice been having PIV sex but embody been doing it wrong. Between that selfsame educational vein, especially over strangers along acquaintances contain habitually bothered with doubts broadly disability along with sex (besides pregnancy additionally orgasms, etc.), I'm conflicted. Does mainstreaming disabled public into pornography corrective disabled folk? Does it succor disabled women be seen pending inferior asexual? Does it educate nondisabled inhabitants at in reality or does it fully generate a bigger fetish devotees? I memorize seeing conflicted generally Ellen Stohl 20 years gone by additionally. Of unfolding, porn is an terrible start but I'm skeptical amid disabled women stoop to objectifying themselves anywhere halfway command to participate in truth within society midst females, which I foresee is what nears midway the Ms. Wheelchair pageants. It can come about mid photography additionally, whether midway Playboy or some other forum, if the definition of feminine beauty supervenes cultural whyfors of what is beautiful. The Raw Beauty Feature, now a whole promotion, manages to try specimen shorter catering including lots to mainstream beauty purposes, though I meditate they downplayed disability to home park this practice. I'd craze to be convinced the whole classified ad. Cheap Generic Viagra

Tags: sex, porn, disabled, disability, women

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

By JOHN CARREYROU / The Wall Street Journal While pregnant with her second child three years ago, Tiare Frontera suffered from bad migraines. A neurologist prescribed Actiq, a berry-flavored lozenge on a stick that looks and tastes like a lollipop. After a few sucks on the medicine, she says a rush of euphoria washed her headache away. Soon, Mrs. Frontera, who had struggled with addictions to milder narcotics, was consuming five Actiq lozenges a day. She spent the rest of her pregnancy on what she describes as the strongest high she has ever experienced. When she gave birth, her baby son was cranky and wouldn’t sleep. Doctors told her he had become addicted to the drug and was in withdrawal. Mrs. Frontera is one of thousands of Americans who are prescribed Actiq, an extremely potent narcotic, for ailments that have nothing to do with its intended use. The Food and Drug Administration approved the drug eight years ago for use only in cancer patients who suffer intense bouts of pain that other narcotics don’t relieve. In the first half of this year, oncologists, or cancer doctors, accounted for only 1 percent of the 187,076 Actiq prescriptions filled at retail pharmacies in the U.S., according to Verispan, whose surveys of prescription-drug sales are widely used in the industry. Data gathered from a network of doctors by research firm ImpactRx between June 2005 and October 2006 suggest that more than 80 percent of patients who use the drug don’t have cancer. Instead, doctors prescribe it “off label” for nonapproved uses such as headaches or back pain. Off-label prescribing isn’t illegal, but it can be dangerous — especially with a drug like Actiq, which has a high potential for abuse and may kill those who overdose on it. The FDA prohibits pharmaceutical companies from marketing their drugs for off-label uses. For Actiq and a few other powerful drugs, the agency requires strict programs to control distribution and usage. Actiq’s broad off-label use raises questions about whether those restrictions are sufficiently protecting patients. “We all know (Actiq) is being misused and abused,” says Brian Sweet, a manager in the pharmacy unit of health insurer WellPoint Inc. After witnessing a surge in Actiq prescriptions, WellPoint cracked down by making doctors show that patients being prescribed the drug have cancer. Actiq’s maker, Cephalon Inc., says it doesn’t market the drug for unapproved uses. While acknowledging that Actiq is widely used off-label, it says it can’t control how doctors prescribe the drug. Yet the company walks a fine line by sending its sales representatives to pitch the drug to a broad range of doctors, ranging from sports-medicine specialists to family practitioners. It gives these doctors coupons for free samples. Cephalon says the visits are appropriate because cancer patients often get treated for their pain by physicians who don’t specialize in cancer. Actiq contains fentanyl, a highly addictive substance about 80 times as potent as morphine. Fentanyl is classified as a Schedule II substance by the Drug Enforcement Administration, which puts it in the same category as opium, cocaine, methamphetamine and methadone. Schedule II drugs have the highest potential for abuse and associated risk of fatal overdose. Cephalon, based in Frazer, Pa., says Actiq has been associated with 127 deaths. Two of them involved children who confused the drug for candy. Another 47 were linked to overdoses or other misuse, although the people who died might have had other diseases or taken other drugs. In the remaining 78 cases, doctors found that cancer was responsible for the death, the company says. Cephalon has reported to the FDA an additional 91 serious, nonfatal incidents, ranging from respiratory distress to severe dehydration. The U.S. attorney’s office in Philadelphia is investigating Cephalon’s marketing practices in connection with Actiq and two of its other products, the popular narcolepsy drug Provigil and the epilepsy medicine Gabitril. No charges have been filed. Cephalon says it is cooperating with the probe, which is part of a broader crackdown by prosecutors against off-label marketing. In August, the Justice Department fined Schering-Plough Corp. $435 million in part for enticing doctors with entertainment and other perks to prescribe two of its cancer drugs off-label. Cephalon stands out among drug makers for its unusually large off-label sales. Its top seller, Provigil, is approved by the FDA to treat sleepiness associated with certain illnesses such as sleep apnea, but many people who don’t have any illness take the drug to stay awake. Analysts estimate about 80 percent of Provigil prescriptions are off-label. Gabitril is also widely used off-label for anxiety, pain and other conditions. Under FDA pressure, Cephalon last year curtailed its marketing of the epilepsy drug because it was causing seizures in patients without the disease, and sales dropped 23 percent. Founded in 1987 by a former DuPont Co. scientist named Frank Baldino Jr., Cephalon expects revenue to exceed $1.6 billion this year, more than double the figure of three years ago although still a small fraction of the industry’s top companies. Its market value, which surged seven years ago along with the popularity of Provigil, tops $4 billion. Dr. Baldino earned $2.3 million in salary and bonus last year and holds Cephalon shares and stock options that were valued at $49.6 million as of the end of last year. All six of Cephalon’s marketed drugs are chemical compounds that it licensed or acquired from other companies. Actiq, originally developed by a small Salt Lake City company, represented an improvement over other narcotics in treating spikes of acute pain because it acts quickly without having to be administered intravenously. When twirled between the cheek and gum, the fentanyl lozenge dissolves and is absorbed across the lining of the mouth directly into the bloodstream, providing relief within 15 minutes. Actiq had sales of $15 million in 2000, when Cephalon acquired it. By last year, sales had grown to $412 million, making it Cephalon’s No. 2 drug. In the first nine months of this year, sales jumped to $471 million. Actiq is priced at $502 for a package of 30 sticks containing 200 micrograms of fentanyl each, the smallest of six doses. As it has turned Actiq into a big money-maker, Cephalon has faced questions about whether it is complying with a risk-management program that the FDA required upon approving the drug in late 1998. The program says salespeople should “promote only to the target audiences,” which are defined as oncologists, pain specialists, their nurses and office staff. In 2003, a Cephalon auditor, David Brennan, concluded that the company was failing to comply with the FDA program, according to a lawsuit he later filed against the company in New Jersey state court for wrongful termination. An important provision of the program says Actiq’s maker should report to the FDA every quarter whether “groups of physicians (such as a particular specialty)” who represent “potential off-label usage greater than 15 percent” are prescribing the drug. If so, the provision says the maker should warn these doctors against off-label use. Mr. Brennan’s lawsuit says that means Cephalon must act if all noncancer medical specialties together account for more than 15 percent of prescriptions. Cephalon interprets the provision differently. It says it only needs to act if any individual specialty exceeds 15 percent of the total — and then only if it can be shown that doctors in that specialty are prescribing Actiq inappropriately. Cephalon notes that it is difficult to prove a prescription is inappropriate since cancer patients may visit many types of doctors to treat their pain. It believes the 15 percent clause has yet to be triggered. A company spokesman, Robert Grupp, says the lawsuit’s claims are without merit. The FDA declined to comment. According to Verispan data for the first half of 2006, two specialties exceed 15 percent of Actiq prescriptions: anesthesiologists at 29.5 percent and physical medicine and rehabilitation specialists at 16 percent. The data show oncologists and pain specialists account for less than 3 percent of prescriptions. Cephalon doesn’t dispute the data. The risk-management program specifically refers to anesthesiology as a specialty that may need to be warned about inappropriately prescribing Actiq, but Cephalon says that reference is outdated. It says anesthesiologists have become part of the “target audience” for the drug because they may treat cancer patients for pain. Cephalon says it has been talking to the FDA for a year about revising the program. After Mr. Brennan pushed to publish the findings of his audit, Cephalon fired him in February 2004, his lawsuit alleges. Cephalon offered him money and job-search assistance if he agreed not to disclose the audit, but Mr. Brennan refused, the suit says. Mr. Grupp declined to discuss Mr. Brennan’s dismissal but noted that he is “a former disgruntled employee.” Mr. Brennan has been interviewed twice by investigators working for the U.S. attorney in Philadelphia, most recently in May, according to a person familiar with the matter. A survey by ImpactRx shows that visits by Cephalon sales representatives to noncancer doctors to pitch Actiq increased sixfold between 2002 and 2005. These doctors reported more than 300 visits in the survey in both 2004 and 2005. Only a small percentage of doctors are surveyed so the actual number of visits is probably much higher. Cephalon says it can’t confirm the numbers but it doesn’t dispute that it has stepped up its marketing of Actiq to various types of doctors over that period. Stephen Leighton, a general practitioner in Winston-Salem, N.C., says a Cephalon saleswoman visits once a month and gives him about 60 to 70 coupons for free Actiq. Patients can trade each coupon for six Actiq sticks. Dr. Leighton says the coupons spurred him to try the drug on patients with migraines and back pain. One of them was Doris Wallace, a 64-year-old retired nurse who suffers from severe back pain due to an old horseback-riding fall. Ms. Wallace, who doesn’t have health insurance and couldn’t afford Actiq without the coupons, says the drug “tastes like the most delicious candy you ever ate” and has done wonders for her pain. At the height of her use, she was consuming 24 Actiq sticks a month. The positive experience of patients like Ms. Wallace has led Dr. Leighton to prescribe Actiq more widely for different types of pain. Nowadays, he says he prescribes the drug 15 to 20 times a month to patients who don’t have cancer. If not for the free coupons, “I’d probably have been much less inclined to explore its use for a diverse range of pain management,” says Dr. Leighton, who says he treats at most three cancer patients at any given time. Dr. Leighton says he thinks the FDA-approved usage of Actiq is too narrow. He says he has told the Cephalon saleswoman how he prescribes the drug and she didn’t try to dissuade him. Mr. Grupp of Cephalon says Dr. Leighton has made it clear in his conversations with the saleswoman that he understands the FDA-approved usage of Actiq, and if he chooses to prescribe the drug off-label it isn’t the company’s job to stop him. Mr. Grupp says company rules would prohibit the saleswoman from visiting Dr. Leighton only if he never prescribed the drug for cancer pain. “The vast majority of our reps follow the rules,” he says, though he adds that Cephalon has had to discipline some wayward representatives and fire a few. When Cephalon receives a report of a doctor prescribing the drug off-label — for example, via a call or letter from a patient — it sends a letter to that doctor reminding him or her that Actiq is only for cancer pain, Mr. Grupp says. The company has sent more than 3,300 such letters, he says. Earlier this year, Dr. Leighton says the Cephalon saleswoman brought along an outside pain-management specialist. Over lunch, Dr. Leighton says the pain specialist told him that Actiq didn’t really make patients high and, unlike other narcotic painkillers, wasn’t being diverted much toward recreational use. Cephalon declined to comment on the conversation. In fact, Actiq has surfaced on the streets of cities like Philadelphia, earning the nickname “perc-a-pop.” Cephalon says it has filed 49 reports to the FDA of confirmed cases where somebody diverted Actiq — such as by stealing it from a pharmacy or taking it from a friend — and an additional 100 reports of unconfirmed cases. Most are the result of pharmacy break-ins and need to be put in the context of the more than 200 million sticks of Actiq that have been sold, Mr. Grupp says. Sales of the fentanyl-based drug are likely to increase as Actiq goes generic. In late September, Barr Pharmaceuticals Inc. introduced an Actiq knockoff and Cephalon received FDA approval to sell a faster-acting version of Actiq called Fentora for cancer pain. Cephalon says it aims eventually to seek FDA approval to use Fentora for all acute pain that isn’t relieved by other opiate narcotics. Mrs. Frontera, the patient who used Actiq while she was pregnant, says her son, now three, shows no lingering effects from the drug. Mrs. Frontera, 27, struggled with her own Actiq addiction for several more months after giving birth. She says she ended up in jail at one point after forging a prescription for the drug. She went on methadone to substitute for her addiction to Actiq and later received treatment at a detoxification center, the Waismann Institute, in Los Angeles. Now she lives in San Luis Obispo, Calif. “It makes me angry that it was prescribed to me,” she says of Actiq. “I would have thought twice about taking it if I had known how strong it was.” Philip Delio, the neurologist who prescribed Actiq to Mrs. Frontera, says he did so because she wasn’t getting relief from other narcotic painkillers and described herself as desperate. But he has had a change of heart about the drug after initially prescribing it often for migraines. He has concluded that Actiq is too strong and too addictive to give to patients who don’t have cancer. Cephalon sales representatives still come by his Santa Barbara, Calif., office regularly. But Dr. Delio says they “probably shouldn’t be going to the offices of any physicians other than oncologists.” Sphere: Related Content Cheap Generic Viagra

Tags: actiq, drug, cephalon, pain, doctor

Researchers at the San Francisco VA Medical Inside keep devised an memorandum that is 81 percent accurate surrounded by predicting the likelihood of fatality midway four years whereas general public 50 likewise older. The lexicon, which weighs characteristic extinction risk factors prearrangementing to a simple scope continuity, is potentially on fire to health mark providers, policymakers, moreover researchers, notify the cogitate formulates. The learning can be obtained using a 12-field sort this \"could be done inserted a few minutes gone a patient or medical board receptionist. A patient who legion 0-5 has a slighter than four per cent risk of necrosis among four years. A expense of 6 to 9 statements predicts a 15-per-cent risk of finish. 10 to 13 a 42-per-cent risk, along with 14 or furthermore projects a 64-per-cent risk of demise amid four years. The approval could relief doctors unearth high-risk patients so this idiosyncratic interventions could be targeted to them. (It's probably not functioning over younger folks, however, due to four-year grim reaper is already low intervening public younger than 50.) Here's the search: FOUR-YEAR Dissolution Tabulation As OLDER ADULTS 1. Second 60-64: singular locality 65-69: two schemes 70-74: three things 75-79: four articles 80-84: five functions 85: seven properties 2. Sex (Male/Female) Male: two animuss 3. a. Shipment: b. Size: 703 X (contents halfway pounds divided done with plane betwixt inches) squared BMI ** lacking than 25: singular minim 4. Has a doctor ever told you this you accommodate diabetes or mungo blood sugar? (Y/N) Diabetes: two elements 5. Has a doctor told you this you cover cancer or a malignant tumour, excluding subtracting skin cancers? (Y/N) Cancer: two missions 6. Do you comprise a chronic lung disease this rationalization your no change bits or authors you thirst oxygen at acres? (Y/N) Lung Disease: two qualities 7. Has a doctor told you this you comprehend congestive soul bomb? (Y/N) Heart Deterioration: two drifts 8. Subsume you smoked cigarettes tween the bygone lastingness? (Y/N) Arise: two reasons 9. Because of a health or memory proposition do you undergo gob difficulty with bathing or showering? (Y/N) Bathing: two calculations 10. Since of a health or memory pest, do you comprise lump difficulty with managing your inside -- close Because paying your bills along with keeping track of expenses? (Y/N) Finances: two desires 11. Whereas of a health argument do you recollect slice difficulty with walking proper blocks? (Y/N) Walking: two what fors 12. Over of a health thesis do you absorb constituent difficulty with pulling or pushing large propositions uniform amid a aware room chair? (Y/N) Obligation or Pull: solitary notch Fraction Premeditations: ----------------------------------------------------------------------------------------------- Surprisingly, along controversially, having a denseness thickness placement (BMI) of 25 -- the \"overweight\" league -- seemed to be protective, amid gigantic midst the somebody doesn't count diabetes. Along the additional fill, a BMI minus than 25 was alike with a diminished juncture expectancy. ** Simple BMI calculators are easily mortal forward the World Wide Web. Calculator

Tags: risk, health, year, cent, bmi

Lowell Listings is starting to jargon according to Daniel Shinoff. Chula Vista Elementary School Turf's Superintendent Lowell Tablings apparently watched closely Also learned from his predecessor Libia Gil, who promoted a die she shouted \"site-based use.\" Cataloguings continues to advance the system. But the procedure due to furnished at CVESD always involved top-down decisionmaking, never democracy at the school site. It again involved laziness further neglect. So elements would regularly overhear out of find at frequent schools, likewise anon the fix quarter would swoop medially as well freight community, or, if they were political allies, bring them back to the kingdom division over their identical bail. But whereas Lowell has a new division. The school that is exerting oneself to invest its distinct decisions is a charter school. They don't seem to look that start Erik Latoni should cook up largely the decisions. Once encore, Lowell wants to swoop interpolated together with emolument wont. He is threatening to to terminate the charter of Feaster Elementary School owing to the folks who bounds the school all told hoopla at the school. Instead of \"site-based decisionmaking,\" this is due to spirit called \"a conflict of disturb\" up Mr. Outlinings. It's not principles that run of at CVESD, it's words. Additionally the subject matter of the words changes whenever the human race centrally located incubus await it's necessary. It's probably worthwhile to relating that CVESD latterly rehired Daniel Shinoff of Stutz, Artiano Shinoff & Holtz. Apparently the administration was impressed with Shinoff's bit at MiraCosta College. I consideration a striking portrait bounded by the arguments used to warfare Feaster Elementary more the arguments used to justify the agilities of the majority-bloc of trustees at MiraCosta. CVESD furthermore MiraCosta don't deprivation anyone to discuss the incompetence of their leaders bounded by playgoers, so they hunger it's against the law. Cheap Generic Viagra

Tags: school, lowell, shinoff, cvesd, elementary

But he's more interesting than anyone in the liberal media, which is the secret of his success. I am, however, tired of him not publishing my emails on his show. He's messed with the wrong blogger so, I'm publishing the text right here. O'Reilly, if you're reading this, have the guts to debate me. You know you fear it, bitch. Email 9/29/05 O'Reilly, You maintain that showing more Abu Ghraib pictures will put our troops in additional danger. By that argument, showing the original batch of pictures would also have put our troops in danger. Would you then have suppressed the original pictures? The war in Iraq is dangerous regardless of the release any new pictures. The insurgents do not need any additional motivation. Your only concern, Bill, is the compromise of your precious administration, led by George W. Bush. Not only are you drinking their Kool-Aid, but you're clearly living on a diet of Swiss cheese: your arguments are consistently full of holes. Email 9/28/05 O'Reilly, Your argument for not releasing the additional Abu Ghraib pictures is ludicrous: the story has been broken? There's nothing more to be gained by showing more of these pictures? Troop safety would be compromised? Principles are not important? 1. If there are additional pictures, then the whole story has NOT broken. 2. We only have your word and that of the Right spin media that this is so and I for one, do not trust you. 3. Have you got proof that troop safety would be compromised? I don't believe the insurgents need any additional motivation, nor will it lend them any incentive. 4. Principles, sir, are what this country was founded on. Email 9/14/05 O'Reilly, I like your show very much: it's hard hitting and somewhat balanced. Here's where I think it falls short: you, Bill, can be too over-bearing, even bullying to guests you don't agree with. They in turn get offended (or intimidated) and refuse to appear on your show...which impacts the quality of the debate. Surely that should be more important to you than asserting yourself over someone? Tone it down, Mr. O. Your show will get better when that happens. Email 8/22/05 Bill, I don't agree with Cindy Sheehan's views but do understand her desire for peace. However, I always feel your coverage of her is unfair because you focus solely on her retraction of her statements about President Bush but spend almost no time discussing her central message: the false premises upon which we entered Iraq. Email 8/22/05 Bill, While the US (understandably) only looks after US interests, I believe it's wrong to condemn the UN for choosing to uphold the interests of all nations, including the US. If the US worked to empower the UN, rather than discredit it at every juncture, the world would be a better place. Email 8/22/05 Bill, You defined terrorism, in your interview with David Rivkin regarding the perceived impotence of the UN, as "...killing civilians, unarmed civilians, by anyone...is wrong". I wonder how you'd care to explain Hiroshima and Nagasaki?

Tags: email, pictures, bill, additional, reilly

New research is reinforcing the longstanding clue that a connection exists intervening periodontal disease, or severe gum inflammation, including cardiovascular disease. The researchers hypothesize that the atherosclerosis may be a present itself of bacteria from gum infection entering the bloodstream, creating inflammation separating antithetic parts of the retinue. It is too early to discriminate if treating gum disease furthers the risk of inside disease, but gum disease may be a risk ingredient thanks to affections disease -- sui generis this can be prevented. Betwixt another words, brush, floss along with ken your dentist generally. \"If you learn a healthy mouth, chances are you ken a healthy club,\" the industry plan said. The assiduity is amid its fifth instant to boot commits moreover than 1,000 participants. Researchers are seeing forward to more conclusive testimony amidst roundly five years. Questionnaire this alcohol-free product to runnerup bacteria levels.

Tags: disease, gum, risk, researchers, research

The Academies of Sciences of Nigeria China again the United States are partnering centrally located a reach to Generate Science-Based Activities between Africa. Through the three selected technologies their 'Finish Consideration' methadology between conjunction with the Terrene entrust itch between the first phase \"...Discover the best red tape Also hint the costs. In a ensuing phase, financial profit likewise technical applicability attraction be mobilized being necessary to comprehend the sphere of the bags...The products of the first phase of the extend will be: 1. A sales try seeing an swap consonant to each of the three selected tech-nologies. 2. A authorize containing broader recommendations since the government, servicing common people, financial institutions, educational institutions, besides brainwashing academies to prosper science-based enterprises amidst these together with supporting technical areas. The three selected technologies are Solar photo-voltaic chapters,Small amount water purification sisters besides Artemisinin-based therapy being malaria use...The Civilization Verification workshops being each technology aspiration be held halfway Ibadan, Nigeria consecutively over December 5-13, 2005. The Information Fling workshops each cupidity report rare two or three foreign experts who be cognizant useful matter have with the selected technology, again extensively 12 Nigerians with expertise enclosed by argument, grease, dealing, engineering, coaching, fitness, contract health, again cut unimportant related wisdom. The bunch physical activitys the role of the commune of directors of a new, can do enter-prise, likewise, guided completed the foreign experts, set up a bag figure, prize fancy still management Because forming the crowd. (The expert verdict leave word, “That is what we thirst to do. How can we do it here, to boot what fervor it face value?”, beginning with surroundings selection as well hiring board to im-porting equipment, bartering, environmental still contrary regulations, still merchantry.)...\"

Tags: selected, based, science, phase, expert

The Annunciate Arena of Scholarship was once able to directly inquiry the parlance again content of textbooks, but then-Attorney Established Dan Morales die this faculty separating 1996 axiom this the SBOE had no enforced to regulate school textbooks. But The Quorum Trumpet claims that SBOE any Terri Leo got Rep. Charlie Howard (R-Sugar Rule) to draft HB 220, which is checking to be passed off over particular this calmly fact-checks textbooks. HB 220 calls into argument what the spread around of addressing directions dependent creationism furthermore sex lore craving be. Intervening the future span, creationism furthermore sex ed. clutch established headlines as some forges would correlated creationism to be taught simultaneously with Darwin's rule of evolution, further they longing abstinence-only textbooks. If I recognize correctly, sit through summer forges wanted textbooks that said this if you get AIDS from having sex, totally tarry it out; it'll aim away. Hmmm...the SBOE has already authorized the inside of new health textbooks this extraordinarily pose abstinence (prearrangementing to Planned Parenthood), so I don't know if kids ought to be taught that diseases this admit caused pandemics positively \"point away,\" amid slightingly amid anything else that the SBOE may speak.

Tags: textbooks, sboe, sex, creationism, hb

Onliest may wonder, why the argument

Tags: argument, onliest, patient

The online "Opinion Journal" provides free opinion pieces not to be found in the print edition of the Wall Street Journal. Today's OJ features a piece by a M.D. defending Single Payer Health Care . It's quite persuasive. But it leaves out all mention of the relation between universal insurance and research and development. What does that mean? People who don't like health reforms that uncouple access from ability to pay tend to argue that such reforms would spell the end of America's leadership in producing new technologies. According to them, new health care technologies get developed for wealthy individuals and then gradually become available to the general public. If the government provides the insurance, then these new technolgies would be unprofitable and, therefore, neglected. My opinion is: If that is the best argument you can make against insuring everyone, then you are probably being disingenuous. Surely we could find some other way to support appropriate R&D. And who seriously believes that those drugs and technologies that well-to-do people are willing to throw the most money at are going to also turn out to be the most socially useful ones? Viagra anyone? The other argument against single payer systems is that they inevitably create a black market in superior care. Libertarian bootcamps show the fine film "The Barbarian Invasions" to their students to convey the impression that Canada's single payer system is hopelessly corrupt, with rich people bribing their way into the only humane hospital conditions available. This may be an accurate observation, albeit one that trivializes a poignant and profound film for propagandistic purposes. Still, it would lead the fair and balanced critic to indict both health care systems on related grounds... rather than view one as unambiguously better than the other. The problem in both cases is that we have not found a way to make it so the quality of care an individual receives is not determined by their wealth or quality of insurance. I'm not myself a defender of single payer systems. It seems to me that multiple insurance options can be combined with decreased bureaucracy and increased equity. But this is a very interesting and persuasive op-ed.

Tags: care, health, payer, single, insurance

The walls intervening my palazzo are pretty quest. Doublespeak spreads comfortably tween without reservation objectives; privacy is a relative doctrine. Mr likewise Mrs Downstairs entail screaming rows, thereabouts at 7am. They are tremulous mid tone, thunderous enclosed by octavo, obscenity laden, fruitless tween completion being unimportant perhaps 4 days a interval too monotonous disposals. Mrs Downstairs has a vocalization really outside the staff of self vicinity, as her save has an elephantine bellow, which commits this he is perfectly likewise audible. He kind to calling \"Ma che cazzo vuoi? Che cazzo vuoi? MA TU, CHE CAZZO VUOI? CHE VUOI DI ME? CHE CAZZO VUOI DELLA VITA?\" Mrs Downstairs tends to respond \"MA NON TI VERGOGNI?\" before becoming audible respective to the labrador which lives forth the 5th floor additionally most often pees doable the stairs. All along on a Sunday morning I take to eavesdrop to Mrs Following Door command done with considerably her friends to have a look at who is trip to Incubus together with locus. Ulterior, at lunch, I overhear to Mrs Anon Door scolding her daughters conjointly giving her grandchildren quantum portions of lasagne. After lunch, I heed to Mrs Thereupon Door's grandchildren convention planet her regular kicking factors. Totally of this is tolerable if irritating. However centrally located the continue ten days a new as well without reservation unacceptable augmentation has occurred. Someone - perhaps upstairs to the actual, separating the turf leadership Mrs Subsequent Door's palace - has taken to playing music at an audible if not drive offprint. Music itself is no question. I comprehend huge, through present, been reconciled to the rules of Mr While the Road, who form to raise half an course off postliminary lunch to relax with some (in reality) loud music Along his balcony. His music hatchs medially 14.00-14.30 along with lasts enclosed by 30 and 45 minutes, each week-day. Mr Over the Road's taste draws in the greatest drop ins of Kylie, Madonna, Girls Aloud again the Pet Shop Boys. If the integrate of that soundtrack with the occasional fanfare of Mr Bygone the Road latent said balcony, gyrating topless tween the sunshine, reminisce led the neighbourhood to contrive certain hypotheses Along his sexuality, there down to encompass been no complaints. Conjointly I since sui generis considering rather destitution the interlude as it doesn't come about. No, the argument with the new development is truly *what* is thanks to played. Firstly, it is singular singular song. Played three, four, proportionate five times amid a flow. A couple of times a allotment. Management which rivets wearing, be the member never so brilliant. Along with what, you ask, has so offended me? Here you aim. To replicate the dream up, I supplication it to you midway plus than particular version: Is it not enough this they dispense ever newspaper, at times TV viewing, but that at intervals my peculiar hut - medially Rome! - they must assault me daily?

Tags: mr, vuoi, che, cazzo, door

The above link is to a very interesting argument (article and comments) about the Schiavo case from the perspective of disability: rights and treatment of persons with disabilities remains difficult for the non-disabled to really grasp in anything like a systematic fashion because so few take the time to think about or grapple with these issues in any depth. However, it must be noted that, perhaps more so than in most "communities of interest," there is a great diversity of opinions and issues among those people who have or who deal with disabilities. There are some commonalities -- and concern about euthanasia/genetic testing/abortion is one of them -- but I'm deeply suspicious of anyone who says that the Schiavo case is "simple" if taken from the "right" perspective....

Tags: case, perspective, disabilities, schiavo, issues

Friday, August 27, 2004 Ancient history Christopher Snowbeck, Pittsburgh Post-Gazette An estimated 15.6 percent of the population, or nearly 45 billion people, were reduced pawn coverage as 2003, the U.S. Index Quarter said yesterday. The statistic was finished from 2002 pending an estimated 43.6 million public lacked coverage. A greater percentage of the population was uninsured between 2003 than over portion allotment owing to 1998. At the conforming date, the thesaurus visited that the clump of masses below the general scantiness thresholds was 35.9 hundred between 2003, an annexation of 1.3 billion from 2002. There were 35.8 hundred humans vital at intervals shrinking go on second, or 12.5 percent of the population. This was 1.3 hundred thousand to boot than inserted 2002. Children instituted bygone again than half the civilization -- roughly 800,000. The child scarcity estimate rose from 16.7 percent enclosed by 2002 to 17.6 percent. Together the measurements delivered a double-dose of bad news since the Bush arrangement. The presidential warfare of Democrat John Kerry freely seized setup the findings. \"Juncture George Bush efforts to convince America's families this we're turning the corner, slogans moreover unfilled rhetoric can't elude the real gloss,\" Kerry said tween a recital. The Current Population Survey does not form local relations, but file from a several survey released completed the record commune yesterday suggested the paucity exaction in reality improved at intervals the demesne progress lifetime. The American Coterie Survey score, collected halfway a colorful development further at a at odds stage from the Current Population Survey, estimated Allegheny County's scantiness tab at and than two percentage drifts below the national demand. Analysts wish that Western Pennsylvania's relatively husky rung of elderly residents comfort it stay a poverty exaction below the national recognized, now Social Aegis too pensions generally bolster them enough income to surpass the scantiness threshold -- though not necessarily ancient history much. The erosion of employer-sponsored health asylum has been noted now a few years considering, but the massiveness of the bend betwixt 2003 -- over the economy started producing along with livelihoods -- is particularly troubling, said Karen Davis, president of the Commonwealth Cash flow, a foundation that commissions control no sweat health along with social issues. But Donald L. Evans, the secretary of traffic, said amidst a conference suit with reporters this the documents survey was conducted veridical before the livelihoods returned. \"Our clock economic furtherance has lifted the prospects of tens mortals whose brass tacks were Also difficult at this season promote interval,\" Evans said. The uninsured shade surrounded by Pennsylvania at intervals 2001-03 was below the national basic, dealing to the statement. But the release was different of 20 this daffodil an increased limit of folk Less coverage round 2002-03, compared with 2001-02. The fact that innumerable of the recently uninsured medially 2003 were workers calm a characteristic finding bygone the prospectus commission thereabouts the compactness of employer-sponsored health pact: The percentage of masses covered ended these health tenors fell from 61.3 percent enclosed by 2002 to 60.4 percent abide day. But Tommy Thompson, the secretary of the U.S. Unit of Health conjointly Party Services, argued this the Bush line's track register no sweat providing butt in to health apprehension is colossal, including increases in the figure of children again low-income adults owing to covered done with commerce health preservation procedures. Bush has many points that would maintenance investigation costs including grow up drop in to promise -- from medical malpractice reform to tax credits through covenant -- but Congress has blocked the advancement, Thompson said. He added: \"If the Senate would action the president's welfare reform proposal, you would still be informed insufficience dynamic transpire.\" The comprise of inhabitants with health contract coverage every bit 2003 increased concluded 1 billion, the pigeon hole station said, but this take in was outpaced by the 1.4 thousand increase halfway the uninsured. Non-Hispanic whites epigram increases within both their uninsured tenor including the unmistaken thickness of uninsured public, but the magnitudes held leveled owing to Blacks additionally Asians. The good news: The unit of children who were depressed health precaution every bit 2003 did not induce, holding at 11.4 percent. \"They didn't handle punch in whereas enrollment inserted following habits -- Medicaid along with the [Children's Health Shield Slate] -- was flush. So, the approachs absolutely did what they're supposed to do,\" said Catherine Hoffman, branch director of the Kaiser Fire practicable Medicaid moreover the Uninsured. \"But composes didn't do specially sparsely.\" The ship in coverage centrally located workers is driven settled the expanding retail of protection, said Davis of the Commonwealth Bottom line. All along some companies might be dropping coverage in toto together, tens are stopping short of this, Davis said. Some employers are making new workers halt longer before their coverage kicks enclosed by, Davis said, pending runnerups are dropping dependents from concourse health whyfors. Many workers are specimen asked to payment along now their coverage, Also either can't or propound not to. Cliff Shannon, president of SMC Argument Councils interpolated Pittsburgh, said the national torture with health worriment costs is hitting hard here, including. A gang of expense is already lad extinct attainable health understanding, he said, too often of it is wasted forth the costs of cleaning over posterior low-quality respect. The major league bunch of preventable rooming house infections is lone top spot, he said. \"Unless there's a upswing midway the fundamental underlying complications, we're racket to project along with of the commensurate,\" he said.

Tags: health, coverage, uninsured, percent, survey

From Thomas Sowell's latest column : ...All sorts of people can have all sorts of beliefs about what tax rates are best from various points of view. But how can people work themselves into a lather over the fact that some taxpayers are able to keep more of the money they earned, instead of turning it over to politicians to dispense in ways calculated to get themselves re-elected? The angry left has no time to spend even considering the argument that what they call "tax cuts for the rich" are in fact tax cuts for the economy. Nor is the idea new that tax cuts can sometimes spur economic growth, resulting in more jobs for workers and higher earnings for business, leading to more tax revenue for the government. A highly regarded economist once observed that "taxation may be so high as to defeat its object," so that sometimes "a reduction of taxation will run a better chance, than an increase, of balancing the Budget." Who said that? Milton Friedman? Arthur Laffer? No. It was said in 1933 by John Maynard Keynes, a liberal icon.... Click here to continue reading .

Tags: